Last reviewed · How we verify
ION363
ION363 is an antisense oligonucleotide that reduces production of apolipoprotein C-III (apoC-III), a protein that impairs triglyceride clearance and increases cardiovascular risk.
ION363 is an antisense oligonucleotide that reduces production of apolipoprotein C-III (apoC-III), a protein that impairs triglyceride clearance and increases cardiovascular risk. Used for Hypertriglyceridemia in patients at high cardiovascular risk.
At a glance
| Generic name | ION363 |
|---|---|
| Sponsor | Ionis Pharmaceuticals, Inc. |
| Drug class | Antisense oligonucleotide |
| Target | APOC3 mRNA |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By inhibiting apoC-III expression through antisense technology, ION363 lowers triglyceride levels and improves lipid metabolism. This mechanism addresses a key driver of hypertriglyceridemia and may reduce cardiovascular events in patients with elevated triglycerides despite statin therapy.
Approved indications
- Hypertriglyceridemia in patients at high cardiovascular risk
Common side effects
- Injection site reactions
- Flu-like symptoms
- Elevated liver enzymes
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ION363 CI brief — competitive landscape report
- ION363 updates RSS · CI watch RSS
- Ionis Pharmaceuticals, Inc. portfolio CI